News and analysis on disease research and diagnostics.
The Belgian company recently received €3.6 million to develop the signature into a clinical test within the next three years.
The company, which also said it is short on funds, may have to pay $18.3 million to Hudson Bay Master Fund if forebearance is not granted for the default.
Developers can use the Zika virus samples to ascertain whether their tests can help distinguish Zika infection from similar diseases.
Investigators will use Biocept's liquid biopsy tests to detect ALK rearrangements both at baseline and to monitor treatment response and resistance mechanisms.
The study, launched today, aims to evaluate the use of liquid biopsy and natural killer cell testing for the early detection of recurrent breast cancer.
